Recent FDA Designation Puts Promising Engineered Cellular Therapy that Reduces Complications of Lymphoma Treatment on Accelerated Path to Market Approval

Newswise — HACKENSACK, NJ – In November 2020, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for a promising engineered cellular therapy called AB-205. AB-205 acts promptly to repair injured vascular niches of organs to prevent or reduce severe toxicities in patients who have Hodgkin lymphoma (HL) or non-Hodgkin [...]

Published February 16, 2021 at 07:20AM. Read full article at Stem Cells in the News Portal.